The ongoing pandemic and accompanying restrictions negatively impacted our net sales and our results of operations in 2020, highlighting the importance of mobilizing and deploying IT-based resources in combination with leveraging the value of other resources and capabilities. We have successfully implemented business continuity plans including establishing a medical advisory group for employees, leveraging work from home infrastructure to facilitate social distancing, limiting sales visits to critical cases, and accelerating capabilities to provide remote physician support. Our internal control over financial reporting is effective at a reasonable assurance level based on established criteria, which underscores the significance of information management capability in providing data and information to users with appropriate levels of accuracy, timeliness, reliability, security, confidentiality, connectivity, and access. We continue to focus our efforts on the health and safety of patients, healthcare providers, and employees while executing our mission of transforming lives through innovative medical solutions to improve the health of patients around the world. The evaluation of our asset recoverability considered disruptions caused by COVID-19, including revised forecasted sales and customer demand, which are critical for strategic resource allocation and operational flexibility. Our strategic focus on digital transformation and technology deployment has become essential in navigating the challenges posed by the pandemic and ensuring operational efficiency. We have increased our investment in infrastructure in emerging markets to maximize opportunities, reflecting our commitment to enhancing our organizational capabilities and market responsiveness. The integration of technology capabilities through acquisitions has also contributed to our ability to adapt to changing market dynamics and consumer demands. We have recorded goodwill impairment charges related to the execution of a definitive agreement to sell our specialty pharmaceuticals business, which emphasizes the need for effective management of our technology portfolio and strategic resource allocation. The ongoing evaluation of our internal processes and the implementation of cost reduction initiatives demonstrate our commitment to maintaining operational agility and performance improvement in a challenging business environment. Our focus on research and development remains strong, as we aim to advance medical technologies and invest in meaningful projects that contribute to profitable sales growth. The establishment of a cross-functional strategic cash management team is a proactive measure to optimize funds and support our core mission, ensuring that we remain resilient and capable of responding to market changes. The impact of the COVID-19 pandemic on our operations and financial performance, as well as its effect on our ability to execute our business strategies and initiatives successfully, remains uncertain and difficult to predict, necessitating ongoing assessments of our operational capabilities and strategic alignment.